Market Overview

UPDATE: MLV & Co Reiterates On Galmed Pharmaceuticals Ltd As Aramchol Grabs FDA Fast Track Designation

Related GLMD
Benzinga's Top Upgrades, Downgrades For July 20, 2018
38 Biggest Movers From Friday

In a report published Wednesday, MLV & Co analyst Vernon T. Bernardino reiterated a Buy rating on Galmed Pharmaceuticals Ltd (NASDAQ: GLMD), and raised the price target from $19.00 to $24.00.

In the report, MLV & Co noted, “Galmed Pharmaceuticals (GLMD) yesterday announced FDA approval for Fast Track Designation of Aramchol for the treatment of non-alcoholic steatohepatitis (NASH). We view the news as positive, however, believe lack of recognition continues for Galmed's potential to be a fast follower in the NASH competitive landscape. With the IND for study of Aramchol in all fatty liver disorders filed in July, the path is now clear for Galmed to ramp up all of its liver disease clinical development programs and quickly gain ground on the competition. We make slight changes to our models, as we now expect a higher probability of approval for Aramchol in 2020. Thus, we maintain our Buy rating on GLMD shares but raise our PT from $19 to $24. We look for initiation of an out-US Ph 2b study in 4Q14 with Aramchol in patients with NASH who also suffer from obesity and insulin resistance as the next catalyst for the stock.”

Galmed Pharmaceuticals Ltd closed on Tuesday at $8.93.

Latest Ratings for GLMD

Jul 2018Raymond JamesInitiates Coverage OnOutperform
Jul 2018Stifel NicolausInitiates Coverage OnBuy
Jul 2018Cantor FitzgeraldInitiates Coverage OnOverweight

View More Analyst Ratings for GLMD
View the Latest Analyst Ratings

Posted-In: MLV & Co Vernon T. BernardinoAnalyst Color Price Target Analyst Ratings


Related Articles (GLMD)

View Comments and Join the Discussion!

Latest Ratings

ETTXWedbushInitiates Coverage On19.0
HRZNKeefe Bruyette & WoodsDowngrades10.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

UPDATE: Wunderlich Securities Upgrades Hi-Crush Partners LP On Great Opportunity In Sell-Off

Wunderlich Securities Refines Projections For Cracker Barrel Old Country Store, Inc.